Orphan drugs in epilepsy
37,00€

Vendu et expédié par : Cultura

État : Neuf


DISPONIBLE SOUS 6 JOURS

Livraison en magasin dès le 00/00/00  

Plus que pour profiter de la promotion
Plus que pour profiter de la livraison dès demain en magasin

stock en magasin

Retrouvez le produit près de chez vous.


*hors livres expédiés à domicile ou en point relais, hors remise et promotion au panier

Réservez en ligne &
retirez sous 2h
Livraison gratuite en
magasin
Retour en magasin
sous 30 jours

Coups de cœur Cultura

Tous les passeurs de culture peuvent partager leurs découvertes !
Tu as aimé ce produit ? Partage dès maintenant ton coup de coeur :

loader
loader
loader
loader
loader
loader
loader
loader

description

descriptif du fournisseur
More than half of epilepsies start before the age of 20 years and nearly 25% of them are refractory.

A tiny proportion of them are even labelled a "rare illness", i.e. one affecting less than 200,000 people in the United States or less than 5 out of 10,000 people in the European Union.

For these patients, two problems in their management arise:


In children, seizures affect an immature brain and can impact its development. It is therefore essential to treat them so that brain development continues as normally as possible.

The rarity of these syndromes does not encourage the pharmaceutical industry to invest in research.


Therefore, there are few drugs available.

However, a few target syndromes with a particularly unfavourable diagnosis. This work outlines 6 molecules in detail that are specifically used in epileptic encephalopathies. Every aspect of these molecules is discussed, including drug development, indication, efficacy, cost, etc.

Drafted by international experts in the field of epileptology, it provides all the necessary information on orphan drugs and their clinical use.
 
Orphan drugs in epilepsy

Orphan drugs in epilepsy

Pierre Genton, Marina Nikanorova

On vous recommande avec votre achat
Orphan drugs in epilepsy

Orphan drugs in epilepsy

37,00
+